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DRUG-INDUCED PHOTOSENSITIVITY 
– A CONTINUING DIAGNOSTIC CHALLENGE
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SUMMARY – When taking diff erent drugs, their possible side eff ects on the skin should be 
considered, including skin reactions connected to photosensitivity. Th is photosensitivity caused by 
drugs can appear as phototoxic reactions (which occur more often) or photoallergic reactions (which 
occur less often and include allergic mechanisms). Th e following drugs stand out as medications with 
a high photosensitivity potential: nonsteroidal anti-infl ammatory drugs (NSAIDs), cardiovascular 
drugs (such as amiodarone), phenothiazines (especially chlorpromazine), retinoids, antibiotics (sul-
fonamides, tetracyclines, especially demeclocycline and quinolones), etc. In recent years, photosensi-
tive reactions to newer drugs have appeared, e.g., targeted anticancer therapies such as BRAF kinase 
inhibitors (vemurafenib, dabrafenib), EGFR inhibitors, VEGFR inhibitors, MEK inhibitors, Bcr-Abl 
tyrosine kinase inhibitors, etc. In patients taking drugs over a longer period of time (e.g., NSAIDs, 
cardiovascular drugs, etc.), a particular problem arises when an unrecognized drug-induced photosen-
sitivity on the skin manifests in summer months. When taking patient histories, the physician/derma-
tovenereologist should bear in mind that any drug the patient is currently taking may be the cause of 
skin reactions. Th erefore, patients who use potentially photosensitive drugs and treatments on a long 
term basis should be warned of the possibility of these side eff ects on their skin and advised to avoid 
direct exposure to sunlight and to use adequate photoprotection. If patients carefully protect them-
selves from the sun, it is often not necessary to stop treatments that include photosensitive drugs. If 
such reactions appear, anti-infl ammatory and antiallergic therapies should be introduced.
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Introduction
Drug-induced photosensitivity is only one form in 
the line of medical eruptions, and indicates the occur-
rence of skin lesions caused by simultaneous infl uence 
of medication and exposure to light1-7. In the past few 
decades, photosensitivity has been reported with an ar-
ray of drugs, and is now recognized as a noteworthy 
medical problem8.
Photosensitive skin reactions can be the conse-
quence of topical or systemic use of the drug, where 
phototoxic or photoallergic reactions can occur as a 
side eff ect8-11. Th us, several hundred drugs or substanc-
es may provoke phototoxic and photoallergic reactions 
and the list of those medications has expanded in the 
last fi ve years8,12.
Phototoxic reactions become visible very soon 
upon exposure to the accountable agent (within a few 
minutes or hours), whereas photoallergic agent visibil-
ity appears slowly (within one or three days after con-
tact with the body)7,9.
Photosensitivity includes a number of interactions 
and photochemical reactions8. Th ereby, the mechanism 
of drug-induced photosensitivity refers to the devel-
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opment of interaction between a chemical agent and 
light, while a photosensitive agent reacts to harmless 
UV radiation9-11. Th ese reactions to drugs are mostly 
stimulated by action spectrum within the UVA (320-
400 nm) and visible light range or sometimes UVB 
(290-320 nm) range. Phototoxic reactions are frequent 
and can occur in the majority of individuals given large 
enough dose of phototoxic drug while being exposed 
to enough light. Th ese reactions can be caused by any 
of these drugs used orally, topically (e.g., creams, fra-
grances, soaps, etc.), or injected. Th ere are many poten-
tial drugs and exogenous agents causing photosensi-
tivity reactions, such as nonsteroidal anti-infl ammato-
ry drugs (NSAIDs), antiarrhythmics, antihyperten-
sives, neuroleptic drugs, antibiotics, retinoids, etc.4,9,10,13. 
Generally, the main systemic drugs inducing photo-
sensitivity are NSAIDs, antimicrobials, and cardiovas-
cular drugs, whereas the main topical agents that cause 
contact photosensitivity are NSAIDs1. Clinically, pho-
totoxic and photoallergic reactions occur in the sun-
exposed areas of the skin, including the face, neck, 
hands and forearms, where various skin lesions can ap-
pear (Figs. 1 and 2).
Although similar in clinical picture, phototoxic and 
photoallergic skin reactions have few distinguishing 
characteristics9-11. Phototoxic disorders have a high in-
cidence, whereas photoallergic reactions are much less 
frequent in the human population. In phototoxic reac-
tions, the amount of agent required for photosensitiv-
ity is large and the mechanism does not include im-
mune reactions but light-activated cell membrane 
compounds and DNA. On the other hand, in photoal-
lergic reactions, the amount of agent required for pho-
tosensitivity is small and the mechanism includes cell-
mediated immune responses (type IV) to a light-acti-
vated compound9,14. In phototoxic reaction, distribu-
tion includes only sun-exposed skin and clinical 
characteristics are similar to exaggerated sunburn, 
whereas photoallergic reaction includes dermatitis 
(systemic administration of photo-allergen causes a 
picture of drug eruption, while topical application of 
the substance causes eczematous morphology)4-10. 
Generally, drug-induced photosensitivity reactions 
can occur in persons of any age. Th ere are data showing 
that skin reactions to drugs appear in the form of pho-
tosensitive eruption in 8% of cases15. Generally, photo-
allergic reactions are more common in men than in 
women. Phototoxic reactions to a drug or treatment, in 
combination with sunlight, involve a complex patho-
genic mechanism. In phototoxic reactions to photo-
sensitive drugs or substances, energy from UV radia-
tion is absorbed by the molecules of phototoxic agents, 
resulting in the formation of substances such as free 
radicals and others which can cause toxic cell damage, 
resulting in skin cell death. Phototoxic dermatitis in-
cludes a complex mechanism of cell damage and com-
prises a complex of diff erent reactions9. Th ereby, pho-
toactivation of a compound results in the activation of 
electrons (from the stable singlet state to an excited 
triplet state), which then return to a more stable con-
fi guration and transfer their energy to oxygen. Th us, 
reactive oxygen intermediates (e.g., singlet oxygen, su-
peroxide anions, and hydrogen peroxide) damage cell 
membranes and DNA. Th is includes the signal trans-
duction pathways and production of proinfl ammatory 
cytokines and arachidonic acid metabolites, resulting 
in skin infl ammatory response4,9. Clinically, phototoxic 
lesions on the skin are usually noticed relatively quick-
ly (within 5-20 hours from exposure) by lesions in the 
sun-exposed areas, with erythema, edemas, blisters, 
exudates and desquamation, followed by the possible 
additional delay of hyperpigmentation (Figs. 1 and 2).
On the other hand, photoallergic reactions develop 
only in a minority of individuals exposed to the com-
bination of a compound (mostly systemic drugs) and 
UV light6-9. Th e amount of drug required to elicit pho-
toallergic reactions is considerably smaller than that 
required for phototoxic reactions. In photoallergic re-
actions to drugs infl uenced by UV radiation, there is a 
change of the molecule form into a new matter, caus-
ing response of the immune system and it can extend 
to all parts of the body. In doing so, UV energy causes 
binding of the drug as a hapten to proteins in epider-
mal cells, creating an antigen which synthesizes lym-
phocytes in the vicinity; all this occurs in the predis-
posed and previously sensitized person (type IV reac-
tion)9,14. Reactions in a sensitized person can occur 
after repeated exposure to the drug and sunlight and 
are manifested in the skin some time later than photo-
toxic reactions (beginning within 24-72 hours after 
exposure to drug and light).
Clinically, photoallergic reactions to a drug usually 
manifest as a pruritic eczematous eruption, and in the 
acute phase there is erythema and vesicles, while more 
chronic exposure results in erythema, lichenifi cation 
and scaling7-10,15. Opposed to phototoxic reactions, pho-
toallergic skin lesions can also spread out of the sun-
exposed area, and hyperpigmentation does not  occur.
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Phototoxic eff ects of the drugs can also be used for 
therapeutic purposes, e.g., application of a photosensi-
tizer such as psoralen and aminolevulinic acid. Th us, 
psoralen and ultraviolet light therapy (UVA) are com-
bined as a type of phototherapy (PUVA), which is used 
to treat diff erent skin diseases. Th ereby, psoralen makes 
the skin more sensitive to UV light where psoralens 
intercalate within DNA. Th us, monofunctional ad-
ducts are formed, and after exposure to UVA radiation, 
bifunctional adducts within DNA appear, although it 
is still not known how bifunctional adducts cause pho-
tosensitivity9. Also, photodynamic therapy (PDT) is a 
treatment which also uses photosensitizing agents 
(e.g., topical aminolevulinic acid). Th e phototoxic ef-
fect of the agents may cause skin lesions (e.g., actinic 
keratoses) to disappear or decrease in size12.
In addition, drugs with potential photosensitivity 
may have other skin manifestations, for example, por-
phyria (e.g., liver damage by oral contraceptives) or 
lupus erythematosus (e.g., hydralazine).
Drugs and Substances Associated 
with Sensitivity to the Sun
It is noticeable that drugs and substances have dif-
ferent potential for causing skin photosensitivity. Th e 
drugs which are often associated with photosensitivity 
reactions are NSAIDs (e.g., ibuprofen, ketoprofen, 
piroxicam, diclofenac), cardiovascular drugs (furose-
mide, amiodarone, thiazides), antibiotics (tetracyclines, 
ciprofl oxacin, sulfonamides), psoralens, neuroleptic 
drugs such as phenothiazines (especially chlorproma-
zine), oral contraceptives, retinoids (isotretinoin, 
acitretin), antifungals, etc.2,3,9,16,17. Several antibiotics 
and related drugs are associated with photosensitive 
reactions, e.g., amoxicillin, ciprofl oxacin, clofazimine, 
dapsone, demeclocycline, doxycycline, enoxacin, fl ucy-
tosine, griseofulvin, lomefl oxacin, minocycline, nali-
dixic acid, norfl oxacin, ofl oxacin, oxyfl oxacin, oxytetra-
cycline, pyrazinamide, sulfonamide, tetracycline, trim-
ethoprim, etc.9,15-17.
In general, it is noted that photosensitive reactions 
are often induced by compounds with halogen ele-
ments (amiodarone, chlorpromazine, fl uoroquino-
lones, chloroquine, hydrochlorothiazide, etc.). Amiod-
arone (antiarrhythmic) is especially connected to the 
common incidence of photosensitivity reactions, de-
pending on therapy dose and duration. Usually, symp-
toms develop within two hours of sun exposure in the 
form of burning sensation and erythema, and some-
times occur as graphite-gray pigmentation in sun-ex-
posed areas. Th e incidence in the population of pa-
Fig. 1. Phototoxic reaction caused by doxycycline. Fig. 2. Phototoxic reaction caused by antihypertensive drug.
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tients with prolonged use of amiodarone reaches near-
ly 75% according to various sources, but they are often 
misdiagnosed or overlooked18. After drug discontinua-
tion, photosensitivity may last for up to another four 
months, with gradual fading of lesions over months to 
years. In most cases, these eff ects are reversible and 
disappear after discontinuation of the drug.
Photosensitive reactions are also commonly related 
to chlorpromazine (antipsychotic), particularly when 
administered in high doses, and can cause skin lesions 
like burning and painful erythema (appearing in a few 
minutes after exposure) which can last for more than 
24 hours, and sometimes golden-yellow or graphite-
gray pigmentation may occur, mainly on sun-exposed 
areas15.
In recent years, photosensitive reactions have ap-
peared with newer drugs such as targeted anticancer 
therapies, for example BRAF kinase inhibitor vemu-
rafenib (observed in 31%), dabrafenib, etc.19. Photo-
sensitivity potential has also been reported with the 
use of epidermal growth factor receptor (EGFR) in-
hibitors, vascular endothelial growth factor (VEGF) 
receptor (VEGFR) inhibitors, mitogen-activating ex-
tracellular kinase (MEK) inhibitors, Bcr-Abl tyrosine 
kinase inhibitors, and other therapies such as chemo-
therapeutics19-22. In addition, photoreactions to biolog-
ics are also possible (e.g., tocilizumab)23.
Medications also diff er in the frequency of photo-
toxic and photoallergic reactions. Some of the drugs 
more frequently cause phototoxic reaction (tetracy-
clines, sulfonamides, furosemide, isotretinoin, acitre-
tin, etc.), whereas others are more likely to cause pho-
toallergic reaction (hypoglycemic sulfonylureas, sun-
screens, dapsone), and some have an equal potential to 
cause both types of reactions (ketoprofen, hydrochlo-
rothiazide, phenothiazines, etc.).
Topical preparations may also provoke photosensi-
tivity reactions. According to research data, the leading 
contact photosensitizers are sunscreens and topical 
NSAIDs24. It is also necessary to consider photosensi-
tivity when using cosmetics, sunscreens, herbal ex-
tracts, etc.25-29. Th erefore, it is always necessary in prac-
tice to have in mind the possibility of reactions to 
topical drugs30.
Besides classic phototoxic and photoallergic reac-
tions, some drugs may also cause a lichen planus-like 
eruption in sun-exposed areas, e.g., demeclocycline, 
hydrochlorothiazide, enalapril, quinine, quinidine, 
chloroquine, hydroxychloroquine, etc.9,31. Sometimes 
photosensitizing drugs may also cause pseudopor-
phyria (skin lesions similar to porphyria cutanea tar-
da), e.g., after exposure to naproxen, nalidixic acid, tet-
racycline, sulfonylureas, furosemide, dapsone, amioda-
rone, etc.16,32.
Diagnosis and Th erapy
Drug-induced photosensitivity remains a common 
clinical problem and is often underdiagnosed1. In rec-
ognizing photosensitivity to a drug, most important 
are complete patient history and clinical appearance4-7. 
Patients who report photosensitivity should be asked 
about the medications they take and the products that 
are applied to their skin15.
In patients who take drugs over a longer period of 
time (e.g., NSAIDs, cardiovascular drugs, etc.), a par-
ticular problem occurs when an unrecognized drug-
induced photosensitivity manifests on the skin in sum-
mer months. Th erefore, when taking patient history, 
the physician/dermatovenereologist should bear in 
mind that any drug the patient is currently taking 
could be the cause of skin reaction.
A clinical picture with the occurrence of skin le-
sions on sun-exposed areas, including the face, neck, 
hands and forearms, usually indicates potential photo-
sensitivity which can be linked with the drug. Extend-
ed reaction usually indicates a systemic photosensitive 
agent, whereas localized reaction points to reaction to 
a topically applied photosensitizer9.
In diagnosing photosensitivity disorders, the most 
important procedure is photo-testing with UVA, UVB 
or sometimes visible light, performed by exposing 
small areas of the skin on the back or inner aspect of 
the forearms with gradually increasing doses of light. 
A positive reaction at the non-irradiated site with a 
stronger one at the irradiated site should be interpret-
ed as both allergic dermatitis and photoallergic contact 
dermatitis reaction to the same compound.
Th e main investigative technique to diagnose pho-
toallergic or phototoxic reactions is photopatch test-
ing, although it is not commonly used24,33-35. However, 
to perform this kind of procedure, proper equipment is 
needed, which is often lacking. In the diagnosis of 
photoallergic contact dermatitis, photopatch testing is 
a crucial/important tool, performed by applying sus-
pected photoallergens to the back in two sets, and sub-
sequent reaction reading4,34,35.
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Currently available testing methods also include 
the photoprick, photoscratch and illuminated intracu-
taneous tests12. If the causative photosensitizer is not 
the test substance but a metabolite of the test sub-
stance, a systemic photoprovocation test can be uti-
lized.
Skin biopsy of phototoxic reactions may also be 
performed, although is not very useful because it often 
shows nonspecifi c changes (epidermal spongiosis, der-
mal edema, mixed infi ltrate of lymphocytes, macro-
phages, neutrophils, etc.), but sometimes shows ne-
crotic keratinocytes in acute stage. On the other hand, 
blue-gray pigmentation is characteristic of phototoxic 
reactions resulting from increased melanin in the der-
mis or deposition of the drug or its metabolites in the 
skin4,9. Histopathologic analysis of photoallergic reac-
tions also includes epidermal spongiosis and dermal 
lymphocytic infi ltrate, with necrotic keratinocytes, 
which is suggestive of photoallergy.
Treatment of phototoxic and photoallergic derma-
titis includes identifi cation and avoidance of the of-
fending drug, symptomatic measures, topical cortico-
steroids, cool dressings, antihistamines, and sometimes 
systemic corticosteroids9-11. In severe phototoxic reac-
tions, the management may even include burn care 
units. Generally, patients are advised to use the sun-
screens with UVA protection with high sun protection 
factor (SPF), but sunscreens could also be causative 
agents, since they often contain para-aminobenzoic 
acid, which can cause photosensitivity of the skin.
On the other hand, it is important to know that 
SPF is not a reliable indicator of protection against 
drug-induced photosensitivity and primarily refers to 
the degree of protection against the UVB range. Pa-
tients with potentially photosensitive agents in long 
term therapy should be alerted to the problem and ad-
vised on proper protection. Such patients should avoid 
exposure to direct sunlight, wear protective clothing, 
and use a cream with high SPF4,5,15. In most cases of 
phototoxic eruptions, it is not necessary to stop drug 
therapy if sun protection is possible. However, in pho-
toallergic reactions, the drug should be discontinued as 
soon as possible since the slightest sun exposure could 
cause serious reactions. If sun protection measures are 
applied on time, it is often not necessary to stop the 
treatments that include photosensitive drugs, but in 
the case that such reactions do show up, anti-infl am-
matory and antiallergic therapy should be introduced.
Although dermatological complications and pho-
tosensitivity usually do not infl uence the outcome of 
therapy and rarely cause discontinuation of treatment, 
they have great impact on the patient quality of life18,36.
Conclusion
Patients who use potentially photosensitive drugs 
and treatments on long term basis should be warned of 
the possibility of these side eff ects on their skin, and 
should be advised to avoid direct exposure to sunlight, 
as well as to use appropriate photoprotection. In order 
to avoid photosensitive reactions, it is essential to know 
the photosensitizing properties of such drugs and to 
advise the patients. If sun protection measures are tak-
en timely, it is often not necessary to stop treatments 
that include photosensitizing drugs. If such reactions 
do appear, anti-infl ammatory and antiallergic thera-
pies should be introduced.
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Sažetak
FOTOOSJETLJIVOST UZROKOVANA LIJEKOVIMA – KONTINUIRANI DIJAGNOSTIČKI IZAZOV
L. Lugović-Mihić, T. Duvančić, I. Ferček, P. Vuković, I. Japundžić i D. Ćesić
Prilikom uzimanja različitih lijekova moguće su nuspojave na koži, među kojima su i reakcije povezane s fotoosjetljivošću 
lijeka. Fotoosjetljivost uzrokovana lijekovima može se iskazati u obliku fototoksične reakcije (koje su češće) ili fotoalergijske 
reakcije (koje su rjeđe i uključuju alergijske mehanizme). Kao lijekovi s visokim fotoosjetljivim potencijalom ističu se amjo-
daron, nesteroidni antireumatici (NSAR), kardiovaskularni lijekovi (kao amjodaron), fenotiazini (osobito klorpromazin), 
retinoidi, antibiotici (sulfonamidi, tetraciklini, osobito dimeklociklin i kinoloni) itd. Posljednjih su godina reakcije fotoosjet-
ljivosti zabilježene i na novije lijekove kao što je ciljana antitumorska terapija, npr. inhibitori BRAF kinaze (vemurafenib, 
dabrafenib), EGFR inhibitori, VEGFR inhibitori, MEK inhibitori, inhibitori Bcr-Abl tirozin kinaze itd. U bolesnika koji 
uzimaju lijekove tijekom dužeg razdoblja (npr. NSAR, kardiovaskularni lijekovi itd.) osobit problem je mogućnost nepre-
poznavanja lijekom potaknute kožne fotoosjetljivosti koja se javlja u ljetnim mjesecima. Stoga bi kod uzimanja anamneze 
bolesnika liječnik/dermatovenerolog trebao imati na umu da bilo koji lijek koji bolesnik uzima može biti uzrok kožnih 
 promjena. Prema tome, bolesnike koji duže vrijeme uzimaju potencijalno fotoosjetljive lijekove i postupke treba upozoriti na 
mogućnost ovih nuspojava na koži te bi ih trebalo savjetovati da izbjegavaju izravno izlaganje sunčevu svjetlu i da primje njuju 
mjere za zaštitu od sunčeve svjetlosti. Ako se na vrijeme započne s mjerama zaštite od sunca onda često nije potrebno preki-
dati liječenje koje uključuje fotoosjetljive lijekove. Ako se takve reakcije ipak pojave treba započeti protuupalnu i protualer-
gijsku terapiju.
Ključne riječi: Uzimanje lijekova, popratni učinci i štetna djelovanja; Fotosenzitivni poremećaji; Dermatitis, fototoksični – 
 terapija; Dermatitis, fotoalergični – terapija
